High immunoproteasome and low constitutive proteasome subunit levels correlate with sensitivity to bortezomib-containing chemotherapy: update from the Children’s Oncology Group AALL1231 trial

High immunoproteasome and low constitutive proteasome subunit levels correlate with sensitivity to bortezomib-containing chemotherapy: update from the Children’s Oncology Group AALL1231 trial

Not available.

Saved in:

Bibliographic Details
Main Authors:	Margot S. F. Roeten, Johan van Meerloo, Suzanne N. van Dijk, Zinia Kwidama, Gaye Jenkins, David T. Teachey, Meenakshi Devidas, Mignon L. Loh, Gertjan J. L. Kaspers, Sonja Zweegman, Gerrit Jansen, Terzah M. Horton, Jacqueline Cloos
Format:	Article
Language:	English
Published:	Ferrata Storti Foundation 2025-01-01
Series:	Haematologica
Online Access:	https://haematologica.org/article/view/11922
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Excess mortality across countries in the Western World since the COVID-19 pandemic: ‘Our World in Data’ estimates of January 2020 to December 2022
by: Gertjan Kaspers, et al.
Published: (2024-06-01)

Ubiquitin Proteasome System in Stress and Disease
by: Dmitry Karpov, et al.
Published: (2012-01-01)

Biosynthesis of lactacystin as a proteasome inhibitor
by: Takeshi Tsunoda, et al.
Published: (2025-01-01)

Downregulation of the immunoproteasome subunit PSMB8 attenuates sepsis-associated acute kidney injury through the NF-κB pathway
by: Min Li, et al.
Published: (2025-01-01)

Renal Thrombotic Microangiopathy Associated with the Use of Bortezomib in a Patient with Multiple Myeloma
by: Jan Van Keer, et al.
Published: (2016-01-01)

Bortezomib-Induced Bronchiolitis Obliterans Organizing Pneumonia
by: E. Vandeix, et al.
Published: (2012-01-01)

Activators of the 26S proteasome when protein degradation increases
by: Donghoon Lee
Published: (2025-01-01)

Molecular insights into the unique properties of the blood‐circulating proteasome
by: Yegor Leushkin, et al.
Published: (2025-01-01)

Bortezomib, thalidomide, and dexamethasone versus bortezomib, lenalidomide, and dexamethasone in transplant-eligible newly diagnosed multiple myeloma: a systemic review and meta-analysis
by: Yin-Che Wang, et al.
Published: (2025-12-01)

Suppression of the Oncogenic Transcription Factor FOXM1 by Proteasome Inhibitors
by: Andrei L. Gartel
Published: (2014-01-01)

An NMR Study of the Bortezomib Degradation under Clinical Use Conditions
by: Adele Bolognese, et al.
Published: (2009-01-01)

Cytokine and Chemokine Profile in Patients with Multiple Myeloma Treated with Bortezomib
by: Paweł Robak, et al.
Published: (2020-01-01)

Involvement of the Ubiquitin-Proteasome System in the Formation of Experimental Postsurgical Peritoneal Adhesions
by: Clara Di Filippo, et al.
Published: (2012-01-01)

Bortezomib Use for a Critically Ill Patient with Angioimmunoblastic T-Cell Lymphoma
by: Motoharu Shibusawa
Published: (2022-01-01)

Remission of Severe, Relapsed, and Refractory TTP after Multiple Cycles of Bortezomib
by: Manu R. Pandey, et al.
Published: (2017-01-01)

Bortezomib-Induced Pulmonary Toxicity: A Case Report and Review of Literature
by: Prakash Kharel, et al.
Published: (2018-01-01)

Effect of bortezomib on the treatment of multiple myeloma: a systematic review protocol
by: Vania dos Santos Nunes-Nogueira, et al.
Published: (2022-06-01)

Case report: Therapeutic use of bortezomib in a patient with Schnitzler syndrome
by: Hua Bai, et al.
Published: (2025-01-01)

Mechanisms of ubiquitin-independent proteasomal degradation and their roles in age-related neurodegenerative disease
by: Taylor R. Church, et al.
Published: (2025-02-01)

Design and synthesis of amino-substituted N-arylpiperidinyl-based inhibitors of the (immuno)proteasome
by: Gobec Martina, et al.
Published: (2023-09-01)

Shikonin Induces Glioma Necroptosis, Stemness Decline, and Impedes (Immuno)Proteasome Activity
by: Xianyun Qin, et al.
Published: (2024-01-01)

Retreatment with Bendamustine-Bortezomib-Dexamethasone in a Patient with Relapsed/Refractory Multiple Myeloma
by: Claudio Cerchione, et al.
Published: (2016-01-01)

Enhancing proteasome activity by NMDAR antagonists explains their therapeutic effect in neurodegenerative and mental diseases
by: Fikret Sahin, et al.
Published: (2025-01-01)

Case Report on Renal Failure Reversal in Lambda Chain Multiple Myeloma with Bortezomib and Dexamethasone
by: Bhanu K. Patibandla, et al.
Published: (2014-01-01)

Bortezomib, Ifosfamide, Carboplatin, and Etoposide in a Patient with HIV-Negative Relapsed Plasmablastic Lymphoma
by: Mehmet Akce, et al.
Published: (2016-01-01)

Oversized cells activate global proteasome-mediated protein degradation to maintain cell size homeostasis
by: Shixuan Liu, et al.
Published: (2025-01-01)

Network Meta-Analysis of Once Weekly Selinexor-Bortezomib-Dexamethasone in Previously Treated Multiple Myeloma
by: Michael Dolph, et al.
Published: (2021-08-01)

Successful Treatment of Plasma Cell-Rich Acute Rejection Using Bortezomib: A Case Report
by: Sara Hashemi, et al.
Published: (2024-01-01)

Treatment of Coexisting Chronic Neutrophilic Leukemia and Light Chain Multiple Myeloma with Hydroxyurea, Bortezomib, and Dexamethasone
by: Evelyn Taiwo, et al.
Published: (2014-01-01)

Successful Use of Cyclophosphamide as an Add-On Therapy for Multiple Myeloma Patients with Acquired Resistance to Bortezomib or Lenalidomide
by: Shigeki Ito, et al.
Published: (2013-01-01)

Targeting enolase 1 reverses bortezomib resistance in multiple myeloma through YWHAZ/Parkin axis
by: Xuejie Gao, et al.
Published: (2025-01-01)

Aspirin inhibits proteasomal degradation and promotes α-synuclein aggregate clearance through K63 ubiquitination
by: Jing Gao, et al.
Published: (2025-02-01)

Proteasome inhibition enhances oncolytic reovirus therapy in multiple myeloma independently of its direct cytotoxic effects
by: Ada Alice Dona, et al.
Published: (2025-01-01)

Longitudinal omics data and preclinical treatment suggest the proteasome inhibitor carfilzomib as therapy for ibrutinib-resistant CLL
by: Lavinia Arseni, et al.
Published: (2025-01-01)

The prognostic value of the platelet-to-lymphocyte ratio in multiple myeloma patients treated with a bortezomib-based regimen
by: Quane Zhang, et al.
Published: (2025-01-01)

Daratumumab for Bortezomib-Refractory Proliferative Glomerulonephritis With Monoclonal Immunoglobulin Deposits in Kidney Allograft: A Case Report
by: Zewei Chen, et al.
Published: (2025-02-01)

Bortezomib, thalidomide, and dexamethasone versus thalidomide and dexamethasone for response rates in multiple myeloma patients: a retrospective study
by: Juan M. Cano-Calderón, et al.
Published: (2025-01-01)

Bortezomib-releasing silica-collagen xerogels for local treatment of osteolytic bone- and minimal residual disease in multiple myeloma
by: Dirk Hose, et al.
Published: (2024-12-01)

Homeobox protein MSX-1 restricts hepatitis B virus by promoting ubiquitin-independent proteasomal degradation of HBx protein.
by: Qian Qiu, et al.
Published: (2025-01-01)

Structural comparison of human and Plasmodium proteasome β5 subunits: informing selective inhibitor design for anti-malaria agents
by: Muhammad Yasir, et al.
Published: (2025-01-01)